Health plans continue to show interest in expanding outcomes-based contracts, according to an Avalere Health study that also found cardiovascular diseases, infectious diseases, and oncology represent the most common therapeutic areas to have these contracts.
Familiarity with outcomes-based contracts is already high among health plans, and a large majority of them are considering expanding their involvement in them, according to a new survey from Avalere Health. The survey involved 50 health plan representatives from 49 different organizations that represent at least 183 million of the covered lives in the United States.
The survey found that one-fourth of plans already have an outcomes-based contract in place, and 85% of those plans are considering more contracts. One-third of plans that do not currently have an outcomes-based contract are considering one.
The most common areas for outcomes-based contracts are cardiovascular disease, infectious disease, and oncology. While cardiovascular and infectious diseases both have clearly defined outcomes, the metrics for oncology outcomes-based contracts are not as well established, according to Avalere.
The survey found that 64% of plans with outcomes-based contracts have a contract in a cardiovascular disease, such as hypercholesterolemia, heart failure, or atrial fibrillation; 42% have a contract in an infectious disease, such as hepatitis C; and 32% have a contract in oncology. Other therapeutic areas where plans have outcomes-based contracts are orthopedics, endocrinology, immune/inflammatory diseases, rare/orphan diseases, and respiratory diseases.
“Our survey results indicate payers are examining outcomes-based contracts in oncology, for which measures for success have been elusive,” Dana Macher, senior vice president at Avalere, said in a statement. “Recent drug launches and a strong oncology pipeline may be compelling plans to explore outcomes-based contracts as a way to help balance access and cost.”
In 2018, nearly all (98%) of respondents were at least somewhat familiar with outcomes-based contracts. Compared with 2017, the proportion who said they were very familiar increased (54% in 2018 vs 48% in 2017).
According to the survey results, health plans are having more conversations about outcomes-based contracts within the organization, with 36% reporting they discuss these contracts a great deal (up from 25%) and 49% saying they have some conversations within the organization (up from 42%).
“Outcomes-based contracts are becoming more of a mainstream topic within health plans,” said Matt Brow, president of Avalere. “While most remain in an exploratory stage, plans that have accrued some experience with outcomes-based contracts are interested in pursuing more.”
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Challenges in developing next-generation cancer therapies persist; research indicates widespread utilization and hurdles in affordability and access to glucagon-like peptide-1 (GLP-1) medications; legislation seeks to legalize therapeutic use of psychedelics in California.
Read More